RCSI spin-out companies

We encourage experienced entrepreneurs and investors to talk to us about the creation of high potential start-up (HPSU) companies based on RCSI IP (spin-outs) or aligned with RCSI’s research focus (spin-ins).

Ireland has several Government-funding schemes to support entrepreneurs seeking to create HPSUs based on IP from higher education institutes

Spin-out companies

RCSI has a number of spin-out companies currently seeking investment and collaboration opportunities, including:

Inthelia Therapeutics

Inthelia Therapeutics is developing new treatments for sepsis – one of the leading causes of critical illness and death worldwide.

PrOBMet

PrOBMet is a precision oncology therapeutics company that is developing targeted treatments for breast cancer brain metastatic patients.

KelAda Pharmachem

KelAda’s mission is to be a catalyst for the integration of green technologies into the manufacture of pharmaceutical ingredients.

Pumpinheart

Pumpinheart is developing a transcatheter implantable left ventricular assist device for the treatment of heart failure with preserved ejection fraction.

OncoLize

OncoLize is developing a thermoresponsive gel drug delivery platform for targeted delivery of chemotherapeutics to solid tumours of the pancreas.

Vertigenius

Vertigenius has developed a digital platform for patients experiencing vertigo, dizziness, and imbalance to enable more efficient patient care and remotely monitored treatment.

Phyxiom

Phyxiom is developing an AI platform that transforms the clinical outcomes of patients with uncontrolled asthma and COPD.

Emerging spin-out companies

RCSI has a number of emerging companies who are actively seeking to raise investment and to build out their teams, including:

MolecuNav

MolecuNav is developing a synthetic fluorination platform which is operationally simple, high-yielding and fast.

LEP Biomedical

LEP Biomedical has developed a platform to combat inflammation and fibrosis in post-surgery glaucoma patients.

Renovate Pharma

Renovate Pharma is developing inhaled, antifibrotic therapies for chronic respiratory diseases, such as idiopathic pulmonary fibrosis.

CellGebra

Cellgebra is developing a digital twin solution to aid rational oncology drug discovery.

Tympulse Medical

Tympulse Medical’s first product is a new technology for the fast and effective repair of damaged tympanic membranes.

ImuPhile Therapeutics

ImuPhile Therapeutics is developing therapies for a novel target in obesity and type 2 diabetes.

StarMAT

StarMAT is developing a novel, patented, non-viral drug delivery technology based on star polypeptides.

DocLeaf

The DocLeaf Project is developing novel device technology for enhancing tissue repair in chronic high recurring wounds.

Hugs@Home

Hugs@Home is a ‘profit for purpose’ company providing guidance and support to first responders and their families.

Get in touch

RCSI’s Office of Research and Innovation can advise investors and entrepreneurs on accessing our pipeline opportunities and explain how RCSI can support spin-out company formation and the technology transfer process.